Alterity Therapeutics Lim... (ATHE)
NASDAQ: ATHE
· Real-Time Price · USD
5.07
-0.09 (-1.74%)
At close: Sep 03, 2025, 3:59 PM
-1.74% (1D)
| Bid | 4.7 |
| Market Cap | 45.96M |
| Revenue (ttm) | 4.78M |
| Net Income (ttm) | -26.1M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -6.76 |
| Forward PE | -5.9 |
| Analyst | Strong Buy |
| Ask | 5.88 |
| Volume | 7,181 |
| Avg. Volume (20D) | 82,159 |
| Open | 5.00 |
| Previous Close | 5.16 |
| Day's Range | 5.00 - 5.16 |
| 52-Week Range | 1.00 - 7.00 |
| Beta | 0.36 |
About ATHE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATHE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATHE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-14.81%
Alterity Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
4 months ago
+26.45%
Alterity Therapeutics shares are trading higher after the company announced that the FDa granted it Fast Track designation for ATH434 for the treatment of Multiple System Atrophy.
